Affiliations 

  • 1 Centers for Disease Control and Prevention, 1600 Clifton Road, MS H24-2, Atlanta, GA 30329, USA. Electronic address: csnider@cdc.gov
  • 2 World Health Organization, Avenue Appia 20, CH-1211 Geneva 27, Switzerland. Electronic address: boualaml@who.int
  • 3 World Health Organization, Avenue Appia 20, CH-1211 Geneva 27, Switzerland. Electronic address: tallisg@who.int
  • 4 World Health Organization Regional Office for the Western Pacific, United Nations Avenue, 1000 Manila, Philippines. Electronic address: takashimay@who.int
  • 5 Office of the World Health Organization Representative to the Philippines, Building 3, San Lazaro Compound, Rizal Avenue, Santa Cruz, Manila 1003, Philippines. Electronic address: abeyasingher@who.int
  • 6 Office of the World Health Organization Representative to Malaysia, Brunei Darussalam and Singapore, 4th Floor, Prima 8, Block 3508, Jalan, Teknokrat 6, 63000 Cyberjaya, Selangor, Malaysia. Electronic address: loy@who.int
  • 7 World Health Organization Regional Office for the Western Pacific, United Nations Avenue, 1000 Manila, Philippines. Electronic address: grabovacv@who.int
  • 8 World Health Organization Regional Office for the Western Pacific, United Nations Avenue, 1000 Manila, Philippines. Electronic address: avagyant@who.int
  • 9 World Health Organization Regional Office for the Western Pacific, United Nations Avenue, 1000 Manila, Philippines. Electronic address: saslam@who.int
  • 10 United Nations Children's Fund East Asia and Pacific Regional Office, 19 Pra Athit Rd, Chana Songkhram, Pra Nakhon, Bangkok 10200, Thailand. Electronic address: aeltayeb@unicef.org
  • 11 United Nations Children's Fund East Asia and Pacific Regional Office, 19 Pra Athit Rd, Chana Songkhram, Pra Nakhon, Bangkok 10200, Thailand. Electronic address: kdaung@unicef.org
  • 12 Office of the World Health Organization Representative to the Philippines, Building 3, San Lazaro Compound, Rizal Avenue, Santa Cruz, Manila 1003, Philippines. Electronic address: wangxia@who.int
  • 13 Office of the World Health Organization Representative to the Philippines, Building 3, San Lazaro Compound, Rizal Avenue, Santa Cruz, Manila 1003, Philippines. Electronic address: shresthaa@who.int
  • 14 United Nations Children's Fund Philippines, 14th Floor- North Tower, Rockwell Business Center Sheridan, Sheridan Street Corner United Street, Highway Hills, Mandaluyong City, Philippines, 1550. Electronic address: corozco@unicef.org
  • 15 Republic of the Philippines Department of Health, Department of Health San Lazaro Compound, Rizal Ave., Santa Cruz, Manila, Philippines, 1003. Electronic address: mtsilva@doh.gov.ph
  • 16 Republic of the Philippines Department of Health, Department of Health San Lazaro Compound, Rizal Ave., Santa Cruz, Manila, Philippines, 1003. Electronic address: mlsucaldito@doh.gov.ph
  • 17 Republic of the Philippines Department of Health, Research Institute for Tropical Medicine, 9002 Research Drive, Filinvest Corporate City Alabang, Muntinlupa City, Philippines, 1781
  • 18 Sabah State Health Department, Tingkat 3, Rumah Persekutuan, Jalan Mat Salleh, 88590 Kota Kinabalu, Sabah, Malaysia. Electronic address: drmj@moh.gov.my
  • 19 Office of the World Health Organization Representative to Malaysia, Brunei Darussalam and Singapore, 4th Floor, Prima 8, Block 3508, Jalan, Teknokrat 6, 63000 Cyberjaya, Selangor, Malaysia
  • 20 Office of the World Health Organization Representative to Malaysia, Brunei Darussalam and Singapore, 4th Floor, Prima 8, Block 3508, Jalan, Teknokrat 6, 63000 Cyberjaya, Selangor, Malaysia. Electronic address: lodhif@who.int
  • 21 United Nations Children's Fund Malaysia, Menara PJH, Level 10, No. 2, Jalan Tun Abdul Razak, Precinct 2, 62100 Putrajaya, Malaysia. Electronic address: hkim@unicef.org
  • 22 Ministry of Health Malaysia, Aras 3, Blok E10, Kompleks E, Pusat Pentadbiran Kerajaan Persekutuan, 62590 Wilayah Persekutuanm Putrajaya, Malaysia. Electronic address: dr_norhayati@moh.gov.my
  • 23 Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne, Victoria, Australia, 3000. Electronic address: bruce.thorley@vidrl.org.au
  • 24 Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne, Victoria, Australia, 3000. Electronic address: Matthew.Kaye@vidrl.org.au
  • 25 National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan. Electronic address: ynishi@nih.go.jp
  • 26 National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan. Electronic address: minetaro@nih.go.jp
  • 27 Ministry of Health Malaysia, Aras 3, Blok E10, Kompleks E, Pusat Pentadbiran Kerajaan Persekutuan, 62590 Wilayah Persekutuanm Putrajaya, Malaysia. Electronic address: jamiatul@moh.gov.my
  • 28 Sabah State Health Department, Tingkat 3, Rumah Persekutuan, Jalan Mat Salleh, 88590 Kota Kinabalu, Sabah, Malaysia. Electronic address: christinarundi@moh.gov.my
  • 29 Office of the World Health Organization Representative to the Philippines, Building 3, San Lazaro Compound, Rizal Avenue, Santa Cruz, Manila 1003, Philippines
Vaccine, 2023 Apr 06;41 Suppl 1:A58-A69.
PMID: 35337673 DOI: 10.1016/j.vaccine.2022.02.022

Abstract

Concurrent outbreaks of circulating vaccine-derived poliovirus serotypes 1 and 2 (cVDPV1, cVDPV2) were confirmed in the Republic of the Philippines in September 2019 and were subsequently confirmed in Malaysia by early 2020. There is continuous population subgroup movement in specific geographies between the two countries. Outbreak response efforts focused on sequential supplemental immunization activities with monovalent Sabin strain oral poliovirus vaccine type 2 (mOPV2) and bivalent oral poliovirus vaccines (bOPV, containing Sabin strain types 1 and 3) as well as activities to enhance poliovirus surveillance sensitivity to detect virus circulation. A total of six cVDPV1 cases, 13 cVDPV2 cases, and one immunodeficiency-associated vaccine-derived poliovirus type 2 case were detected, and there were 35 cVDPV1 and 31 cVDPV2 isolates from environmental surveillance sewage collection sites. No further cVDPV1 or cVDPV2 have been detected in either country since March 2020. Response efforts in both countries encountered challenges, particularly those caused by the global COVID-19 pandemic. Important lessons were identified and could be useful for other countries that experience outbreaks of concurrent cVDPV serotypes.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications